Market Overview

23andMe to Discontinue Access to Health-Related Genetic Tests During FDA Regulatory Review

Related GOOG
What's Dragging Down Google's Results? - Analyst Blog
Market Wrap For April 17: Mixed Earnings Drag The Dow Lower While S&P 500 & Nasdaq End Positive
Stock Futures Zigzag as Traders Parse Earnings Deluge (Fox Business)

23andMe today announced that it will comply immediately with the U.S. Food and Drug Administration's directive to discontinue consumer access to its health-related genetic tests during the ongoing regulatory review process. The company will continue to provide consumers both ancestry-related information and raw genetic data without interpretation. In addition, the company will continue to conduct research using its database of genetic and phenotypic data, and also will continue its educational efforts.

See full press release

Posted-In: News Guidance FDA Management Global

 

Most Popular

Related Articles (GOOG)

Around the Web, We're Loving...

Partner Network

Get Benzinga's News Delivered Free